VK2735-102 part 1 subcutaneous maintenance
63 evidence topics · 9 sources
Objective
Safety, tolerability, and pharmacokinetic objectives with exploratory weight endpoints
Brief summary in the ClinicalTrials.gov record
Evaluation of the transition from weekly to monthly or every-other-week dosing
Location and study date
Initiation in October 2025 and completion of enrollment in January 2026
Top-line results announced in September 2026
Study dates and United States sites in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Study start (actual) | “2025-11-18” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| First posted | “2026-09-24” |
| Site 1 | “Viking Clinical Site #001” |
| Site 1 city | “Lake Forest” |
| Site 2 | “Viking Clinical Site #002” |
| Site 2 city | “Miami” |
Study design
Design as reported with the top-line results: 21-week induction and subcutaneous maintenance
Part 1 as one part of a two-part range-finding study
Study periods in the investor presentation
“6-week screening” (opens the source at this quote in a new tab)
“Weekly SC titration (21 weekly doses)” (opens the source at this quote in a new tab)
“12-week maintenance” (opens the source at this quote in a new tab)
“5-week follow-up” (opens the source at this quote in a new tab)
“Part 1: Subcutaneous (SC) maintenance dosing” (opens the source at this quote in a new tab)
Placebo comparator for the maintenance period
Two study parts and 18 treatment groups in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities” |
| Other study ID | “VK2735-102” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Treatment” |
Original design announced at initiation: 19-week induction with oral and subcutaneous maintenance options
Design stated at completion of enrollment: 19-week induction with oral and subcutaneous maintenance options
Design described in the annual report filed in February 2026
Eligibility criteria
Obesity without other comorbidities
Inclusion criteria in the ClinicalTrials.gov record (both study parts)
Exclusion criteria in the ClinicalTrials.gov record (both study parts)
Age range in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Minimum age | “18 Years” |
| Maximum age | “60 Years” |
Treatment
Two-week titration steps to induction doses of 15.0 to 22.5 mg
Monthly maintenance regimens
Part A treatment arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures
Percentage of week 21 weight loss maintained at week 33
Company view of the weight-loss threshold for cardiometabolic benefit
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at initiation and enrollment at completion
Estimated enrollment across both parts in the ClinicalTrials.gov record
Participants in the induction safety population and with an observed week 21 weight
Participants analyzed in the maintenance period
| Group | Efficacy population | Safety population |
|---|---|---|
| Placebo after 17.5 mg weekly | “(n=27)” | “(n=27)” |
| VK2735 combined every other week | “(n=37)” | “(n=37)” |
| VK2735 combined monthly | “QM (n=65)” | “QM (n=66)” |
Description of analysis sets
Induction and maintenance safety populations
Statistical methods for weight endpoints
Results
Participant disposition
Discontinuations during the 21-week induction period
Discontinuations during the every-other-week maintenance period
Discontinuations during the monthly maintenance period
| Outcome | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
|---|---|---|---|---|---|---|---|
| Discontinued treatment early | “0 (0 %)” | “3 (5 %)” | “0 (0 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (2 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (7 %)” | “0 (0 %)” |
Baseline characteristics
Mean baseline body weight by induction dose
| Group | Mean baseline body weight |
|---|---|
| Placebo (n=15) | “100.0 kg” |
| VK2735 15 mg weekly (n=14) | “108.4 kg” |
| VK2735 17.5 mg weekly (n=118) | “95.9 kg” |
| VK2735 20 mg weekly (n=15) | “101.9 kg” |
| VK2735 22.5 mg weekly (n=14) | “103.0 kg” |
Baseline body mass index requirement
Efficacy results
Change in body weight after 21 weeks of weekly dosing
| Measure | Placebo (n=15) | 15 mg weekly (n=14) | 17.5 mg weekly (n=118) | 20 mg weekly (n=15) | 22.5 mg weekly (n=14) |
|---|---|---|---|---|---|
| Mean change from baseline body weight | “-0.1 kg” | “-17.0 kg” | “-17.0 kg” | “-18.6 kg” | “-17.2 kg” |
| Mean percent change from baseline | “-0.1 %” | “-16.3 %” | “-17.8 %” | “-18.7 %” | “-17.1 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “-16.2 %” | “-17.7 %” | “-18.6 %” | “-17.0 %” |
| p-value vs. placebo | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
Weight-loss thresholds at week 21
Weight loss maintained after transition to every-other-week dosing
Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing
| Measure | Placebo (n=27) | Combined every other week (n=37) | 17.5 mg weekly to 5.0 mg every other week (n=12) | 15.0 mg weekly to 7.5 mg every other week (n=13) | 17.5 mg weekly to 10.0 mg every other week (n=12) |
|---|---|---|---|---|---|
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “90 %” | “83 %” | “90 %” | “97 %” |
| p-value vs. placebo | “-” | “p<0.0001” | “0.004” | “<0.0001” | “<0.0001” |
Weight loss maintained after transition to monthly dosing
Percentage of week 21 weight loss maintained at week 33 with monthly dosing
| Measure | Placebo (n=27) | Combined monthly (n=65) | 17.5 mg weekly to 10 mg monthly (n=16) | 17.5 mg weekly to 15 mg monthly (n=14) | 17.5 mg weekly to 17.5 mg monthly (n=11) | 20 mg weekly to 20 mg monthly (n=14) | 22.5 mg weekly to 22.5 mg monthly (n=10) |
|---|---|---|---|---|---|---|---|
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “85 %” | “82 %” | “84 %” | “90 %” | “86 %” | “85 %” |
| p-value vs. placebo | “-” | “<0.0001” | “0.0016” | “0.0012” | “0.0002” | “0.0005” | “0.0024” |
Continued 17.5 mg weekly dosing through week 33
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events and gastrointestinal adverse events through week 21
| Event | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “7 (47%)” | “116 (70%)” | “11 (73%)” | “83 (69%)” | “10 (67%)” | “12 (80%)” |
| Nausea, mild | “1 (7%)” | “67 (40%)” | “6 (40%)” | “47 (39%)” | “3 (20%)” | “11 (73%)” |
| Nausea, moderate | “0 (0%)” | “3 (2%)” | “0 (0%)” | “2 (2%)” | “0 (0%)” | “1 (7%)” |
| Vomiting | “1 (7%)” | “45 (27%)” | “6 (40%)” | “32 (26%)” | “2 (13%)” | “5 (33%)” |
| Diarrhea | “3 (20%)” | “33 (20%)” | “3 (20%)” | “24 (20%)” | “3 (20%)” | “3 (20%)” |
| Constipation | “1 (7%)” | “18 (11%)” | “1 (7%)” | “12 (10%)” | “1 (7%)” | “4 (27%)” |
Tolerability during the maintenance period
Adverse events after transition to every-other-week dosing
| Event | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
|---|---|---|---|---|---|
| Treatment-emergent adverse events | “14 (52 %)” | “14 (38 %)” | “4 (33 %)” | “5 (39 %)” | “5 (42 %)” |
| Nausea, mild | “0 (0 %)” | “2 (5 %)” | “1 (8 %)” | “1 (8 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Diarrhea | “1 (4 %)” | “2 (5 %)” | “0 (0 %)” | “2 (15 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
Adverse events after transition to monthly dosing
| Event | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
|---|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “14 (52 %)” | “32 (49 %)” | “7 (44 %)” | “7 (50 %)” | “5 (46 %)” | “7 (50 %)” | “6 (55 %)” |
| Nausea, mild | “0 (0 %)” | “3 (4.5 %)” | “1 (6 %)” | “2 (14 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “5 (8 %)” | “2 (13 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Diarrhea | “1 (4 %)” | “3 (5 %)” | “1 (6 %)” | “0 (0 %)” | “0 (0 %)” | “2 (14 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “2 (3 %)” | “1 (6 %)” | “1 (7 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
Study limitations
Summary: study limitations
Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.